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Antiviral polymers are a well-studied class of broad spectrum viral attachment/entry inhibitors whose
activity increases with polymer length and with increased amphipathic (hydrophobic) character. The
newest members of this class of compounds are nucleic acid polymers whose activity is derived from the
sequence independent properties of phosphorothioated oligonucleotides as amphipathic polymers.
Although the antiviral mechanisms and broad spectrum antiviral activity of nucleic acid polymers mirror
the functionality of other members of this class, they exert in addition a unique post entry activity in
hepatitis B infection which inhibits the release of HBsAg from infected hepatocytes. This review provides
a general overview of the antiviral polymer class with a focus on nucleic acid polymers and their
development as therapeutic agents for the treatment of hepatitis B/hepatitis D. This article forms part of
a symposium in Antiviral Research on ‘‘An unﬁnished story: from the discovery of the Australia antigen
to the development of new curative therapies for hepatitis B.’’
© 2016 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Hepatitis B virus (HBV) has affected more than 2 billion people
worldwide, with recent estimates indicating that 248 million of
these individuals still have chronic HBV infection (Schweitzer et al.,.V. This is an open access article u2015). The life cycle and molecular biology of HBV infection have
been previously described by Gish et al., 2015 in this review series.
Complications arising from chronic hepatitis B include the devel-
opment of liver ﬁbrosis and hepatocelulluar carcinoma (Gish et al.,
2015) necessitating therapy to control infection. The disappearance
of the hepatitis B surface antigen protein (HBsAg) from the blood
(HBsAg loss) is considered the best prognostic indicator for the
establishment of control over HBV infection which can endure innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2009). While treatment with HBV polymerase inhibitors like
entecavir and tenofovir disoproxil fumarate suppress HBV DNA
and control the onset of liver disease, they rarely lead to HBsAg
loss and require continual therapy (Chang et al., 2006; Lai et al.,
2006; Marcellin et al., 2008). Treatment with immunotherapies
like pegylated interferon can achieve HBsAg loss but only in a
small fraction of patients and combination treatment with immu-
notherapy and HBV polymerase inhibitors offers only small im-
provements in the rates of HBsAg loss on therapy (Lau et al., 2005;
Marcellin et al., 2008, 2016). As such, there is a need for more
effective treatments for CHB infection, particularly those therapies
which can increase the incidence of HBsAg loss during therapy.
Nucleic acid polymers (NAPs) are the most recently character-
ized member of the antiviral polymer family of compounds which
share the broad spectrum antiviral activity of this class of antiviral
compounds. Importantly, NAPs appear to have a unique ability to
block the secretion of HBsAg from HBV-infected hepatocytes not
observed with other antiviral polymers. NAPs also belong to
another class of compounds, phosphorothioate oligonucleotides
(PS-ONs), which can be safely given to human subjects where they
naturally accumulate in the liver and enter into hepatocytes. This
article provides an overview of the mechanistic properties of
antiviral polymers, the general pharmacokinetic properties of PS-
ONs and a review of the discovery, characterization and optimiza-
tion of NAPs for clinical use and their antiviral effects against HBV
and HDV infection in vivo and in human subjects.
2. Antiviral polymers e a history
A variety of polymeric compounds with antiviral activity have
been described and although this class of compounds comprises
polymers of differing chemical structures (see Fig. 1), they are
known to exert their antiviral effects through similar mechanisms
governed by polymer length and hydrophobicity. Sulfated poly-
saccharides such as heparin sulfate or dextran sulfate are perhaps
the most widely studied members of this class and have been
shown to have a broad spectrum antiviral activity against a wide
range of viruses including human immunodeﬁciency virus, herpes
viruses, respiratory syncytial virus, parainﬂuenza virus, inﬂuenza,
dengue virus and other encephalitic ﬂaviviruses, hepatitis C, hep-
atitis B and hepatitis D (Baba et al., 1988a; Hosoya et al., 1991;
Lüsher-Mattli, 2000; Lee et al., 2006; Basu et al., 2007; Leistner
et al., 2008; Ghosh et al., 2009; Longarela et al., 2013). The anti-
viral activity of sulfated polysaccharides is not dependent on sugar
composition in the polymer chain but is length dependent, with
longer polymers having more potent antiviral activity and depen-
dent on sulfate content, with more sulfated glycan polymers having
greater antiviral activity (Baba et al., 1988b; Hosoya et al., 1991;
Leistner et al., 2008). Sulfation is known to increase the hydro-
phobicity of polysaccharides (Robinson et al., 1984), suggesting that
the conserved requirement of sulfation for antiviral activity deﬁnes
a large hydrophobic interaction domain somehow important in
viral entry. Several studies have demonstrated that sulfated poly-
saccharides interfere with the initial, non-speciﬁc viral adsorption
at the cell surface, likely by interfering with the interaction be-
tween heparin sulfate glycosaminoglycans and viral fusion glyco-
proteins or by preventing membrane fusion between the virus and
the host cell in viruses with class 1 fusion glycoproteins (Hosoya
et al., 1991; Feyzi et al., 1997; Cheshenko et al., 2004; Schulze
et al., 2007).
Similar length and hydrophobic dependent broad spectrum
antiviral activity has been described for a wide variety of polymers
chemically related to sulfated glycans including polystyrene
sulfonate, polyvinylalcohol sulfate, polymethylenehydroquinonesulfonate, napthalene sulfonate and carrageenans (Baba et al., 1990;
Ikeda et al., 1994; Neurath et al., 2002; Bourne et al., 1999; Rusconi
et al., 1996) which are likely a result of analogous chemical features
shared by this class of compounds (Fig. 1).
3. Phosphorothioate oligonucleotides as a drug class:
conserved polymeric features and pharmacokinetic
behaviours
Oligonucleotides are most widely known for their application in
hybridization based technologies such as antisense or siRNAwhich
target speciﬁc, complementary regions of nucleic acids within the
cell (such as mRNA) to affect their degradation via recruitment of
nucleases (Bennett and Swazye, 2010; Wilson and Doudna, 2013;
Sharma et al., 2014). However, in addition to this sequence spe-
ciﬁc functionality, single stranded oligonucleotides are also poly-
mers with polyanionic characteristics which are largely conserved
regardless of their nucleotide sequence. Similar to sulfation in other
antiviral polymers, the hydrophobic (and amphipathic) character-
istic of oligonucleotides is enhanced by phosphorothioation of the
phosphodiester linkages (Agrawal et al., 1990), rendering phos-
phorothioated oligonucleotides heparin sulfate-like in their
chemical properties (Guvakova et al., 1995; Fennewald and Rando,
1995) similar to other antiviral polymers (Fig 1).
Numerous clinical trials have been conducted with single
stranded phosphorothioated oligonucleotides (PS-ONs, used as
antisense oligonucleotides) over the past two decades from which
conserved class behaviours have been established: after adminis-
tration by intravenous infusion or subcutaneous injection, PS-ONs
are rapidly cleared from the blood (1/2 life < 1 h) concomitant
with accumulation in peripheral organs, the most signiﬁcant of
which are the liver and kidney (Bennett and Swazye, 2010), ulti-
mately leading to the upake of PS-ONs into hepatocytes by mech-
anism not yet fully elucidated (Geary et al., 2015). PS-ONs are stable
to nuclease emediated degradation, but degrade slowly overtime,
with the primary route of elimination via the kidney (Geary et al.,
2015). Importantly, pharmacologically active levels of PS-ON can
be maintained in these organs with once weekly dosing which is
generally well tolerated with chronic exposure (Bennett and
Swazye, 2010). As NAPs are PS-ONs, the application of the lessons
learned from effective dosing regimens of other PS-ONs, in the
clinic have been successfully applied in the clinical use of NAPs as
discussed below.
4. Nucleic acid polymers: PS-ONs with sequence independent
and size dependent broad spectrum activity against viral and
other infectious diseases
Nucleic acid polymers (NAPs) are single stranded PS-ONs that
function independently from any antisense or immunostimulatory
effects based on their properties as amphipathic polymers. The
complete structure function relationship for the antiviral activity of
NAPs as well as their molecular mechanism of action was ﬁrst
completely elucidated in a study describing the speciﬁc antiviral
effects of NAPs during the entry of HIV-1 (Vaillant et al., 2006). In
this study, the entry inhibition effect of NAPs was shown to be
sequence independent and size dependent, requiring NAPs longer
than 20 nucleotides for signiﬁcant antiviral effect, with optimal
antiviral activity observed for NAPs 40 nucleotides or longer in
length. This antiviral activity was also speciﬁcally dependent on the
amphipathicity conferred by phosphorothioation in a manner in-
dependent of the increased nuclease stability present with this
modiﬁcation. The structure function relationship required for in-
hibition of HIV-1 entry indicated that a large amphipathic protein
domain in a protein involved in the entry of HIV-1 into the host cell
Fig. 1. Representative chemical structures of antiviral polymers are shown for polyvinyl alcohol sulfate (PVAS), sulfated poly acrylic poly vinyl co-polymer (PAVAS), sulfated
polysaccharides (SPS), polystyrene sulfate (PSS), polynapthelene sulfate (PNS) and nucleic acid polymers (NAP). Composition of phosphate and carboxylic acid groups in PVAS and
PAVAS are variable. Sulfated polysaccharides with antiviral activity can vary in sugar content and sulfate content >2 per sugar residue. REP 2055 and REP 2139 are oligonucleotide
copolymers of alternating adenosine and cytidine optimized for tolerability and activity in HBV/HDV infection (Table 1). Additional modiﬁcations present in REP 2139 (5'meth-
ylcytosine and 20 O-methylribose) to improve NAP administration tolerability in human subjects are shown in bold.
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be the amphipathic alpha helix triplets found in the fusion core in
the gp41 fusion glycoproteins. The NAP-gp41 interaction requires
the amphipathic alpha-helices of gp41 to be uncomplexed (with
their hydrophobic surfaces exposed), a conformation found only in
the pre-fusion conformation of gp41. NAP interaction with this
target domain on gp41 exhibited the same sequence independent
and phosphorothioation and length dependent features as required
for NAP inhibition of viral entry. These interactions were driven by
numerous cooperative hydrophobic interactions between the hy-
drophobic surface of the amphipathic alpha helices in gp41 and the
hydrophobic surface of NAPs as depicted in Fig. 2. This study
showed that NAPs could function as entry inhibitors by blocking
the transition of gp41 into its membrane fusion-competent
conformation.
Uncomplexed amphipathic alpha helix triplex structures anal-
ogous to those present in the pre-fusion conformation of HIV-1
gp41 are conserved in class 1 fusion glycoproteins from many
other viruses susceptible to antiviral polymers (Eckert and Kim,
2001; Lamb and Jardetzky, 2007), consistent with the proposed
antiviral mechanism of other antiviral polymers. Following on from
the initial study in HIV-1, NAPs were subsequently shown to havethe same sequence independent and phosphorothioation (amphi-
pathic) and length dependent antiviral effects in other viruses with
class I fusion glycoproteins including herpesviruses, cytomegalo-
virus, and lymphocytic choriomeningitis virus. (Guzman et al.,
2007; Lee et al., 2007; Bernstein et al., 2008; Cardin et al., 2009).
NAPs and other PS-ONs with NAP-like functionality also prevent
prion protein conversion and block malarial entry into red blood
cells with an activity that follows the same structure function
relationship as observed for NAP activity against viruses with class I
fusion glycoproteins (Clark et al., 1994; Kanagaratnam et al., 1998;
Kocisko et al., 2006), effects which are also described for other
antiviral polymers (Caughey and Raymond, 1993; Xiao et al., 1996;
Vogt et al., 2003). Amphipathic alpha helices analogous to those
found in class I fusion glycoproteins are also found in prion proteins
where they are involved in conversion of the prion protein to its
pathogenic form, and in the Duffy-binding-like domain of eryth-
rocyte binding protein from Plasmodium sp. which is involved in
malarial entry into erythrocytes (Knaus et al., 2001; Singh et al.,
2005) and these domains have been proposed as the target sites
for antiviral polymers (Vogt et al., 2003; Kocisko et al., 2006).
These conserved determinants of biological activity of NAPs, not
only in viral infection but also in other infectious diseases supports
Fig. 2. Current model for universal NAP interaction with uncomplexed amphipathic
protein targets. NAP interaction involves a series of cooperative hydrophobic in-
teractions between the hydrophobic surface of an exposed (uncomplexed) amphi-
pathic alpha helix (red) and the hydrophobic surface of NAPs (green). The hydrophobic
environment is indicated in pink and the hydrophilic environment is indicated in blue.
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cooperative interactions occurring between the exposed hydro-
phobic surface of a large, uncomplexed amphipathic protein
domain and the hydrophobic side of NAPs (which is enhanced in
the presence of phosphorothioation). This interaction prevents
conformational changes in the target or its interaction with other
amphipathic helices, forming the basis of the biological effect of
NAPs.
5. NAP effects in viral hepatitis e a novel targets and a novel
post entry antiviral activity in HBV infection
NAPs have also been shown to be entry inhibitors of HCV
(Matsumura et al., 2009), having the identical structure function
relationship for antiviral effect as observed in viruses with class I
fusion glycoproteins. However this study showed that NAPs do not
block cell attachment but instead block a downstream, post-
binding event required for viral entry. This effect might involve
interactions of NAPs with multiple proteins such as the hypervar-
iable region of glycoprotein E2 or apolipoprotein E, which also have
NAP-like interactions with heparin sulfate (Libeu et al., 2001; Basu
et al., 2004) and are involved in post-binding HCV entry (Basu et al.,
2007; Chang et al., 2007).
Initial evaluations of the antiviral effect of NAPs in HBV infection
were performed in DHBV-infected primary duck hepatocytes (PDH)
(Noordeen et al., 2013a) and conﬁrmed the same sequence inde-
pendent, size and amphipathic dependent antiviral activity against
DHBV infection as found in other viruses. This antiviral activity
included the ability of NAPs to block the HBV life cycle both during
and after viral entry. This novel post-entry activity was not
observed for NAPs in other viral infections (see above) or for other
antiviral polymers in HBV infection (Leistner et al., 2008), sug-
gesting a unique potential for NAPs as therapeutic agents in chronic
HBV infection. More recent preliminary results from initial exper-
iments in HBV infected HepaRG cells and primary human hepato-
cytes (Guillot et al., 2015) suggests that phosphorothioated NAPs
may also block HBV entry in a sequence independent manner but
not in the presence of 20O methyl ribose modiﬁcation (i.e. for NAPslike REP 2139, see below) and no post entry antiviral activity has yet
been observed in these models. However, efﬁcient uptake and
subcellular delivery of PS-ONs is known to be defective in hepa-
tocytes or hepatocyte derived cell lines in tissue culture (Koller
et al., 2011) which complicates interpretation of this preliminary
data. Veriﬁcation of these early results and exploration of the post
entry effects of NAPs in vitro in these models are still ongoing.
While the molecular mechanisms of this post entry effect are still
under investigation, their effects against DHBV infection in vivo and
in clinical trials (as discussed below) currently suggest that NAPs
block secretion of HBsAg from infected hepatocytes and further
may selectively block the secretion of subviral particles.
6. Optimization of NAPs for clinical use in HBV infection
The antiviral activity of NAPs is not only sequence independent
but also tolerates modiﬁcation of all ribose sugars at the 20 position
(Vaillant et al., 2006; Lee et al., 2007; Bernstein et al., 2008;
Matsumura et al., 2009; Noordeen et al., 2013b). This ﬂexibility
permits the optimization of NAPs for tolerability in vivo without
impacting antiviral effect by altering sequence composition and or
incorporating 20 ribose modiﬁcation at any nucleotide position,
advantages unique to NAPs. As is the case for all PS-ONs, the
tolerability of NAPs can be impacted by pro-inﬂammatory/
immunostimulatory effects mediated by recognition of single
stranded oligonucleotides by TLR-7, -8, and -9 or RIG-I (Kawai and
Akira, 2009) which recognize single stranded DNA or RNA. Initial
animal experiments with the prototypic 40mer degenerate NAP
polymer REP 2006 (Table 1) in CMV infected mice and DHBV
infected ducks showed that NAPs could prevent CMV infection in
the spleen and liver or DHBV infection in the liver but that treat-
ment in either mice or ducks was accompanied by hepatotoxicity
and splenomegaly (Cardin et al., 2009; Noordeen et al., 2013b). The
tolerability of REP 2006 in DHBV infected ducks was poor enough to
require dose reduction shortly after treatment began (Noordeen
et al., 2013b). The degenerate nature of REP 2006 (Table 1) results
in the presence of CpG motifs capable of stimulating TLR-9 (Krieg,
2002), consistent with its ability to stimulate cytokine induction
in PBMCs (Cardin et al., 2009). A second candidate NAP, REP 2031,
was designed as a 40mer polycytidine homopolymer (Table 1) with
no CpG motifs and was conﬁrmed to have negligible cytokine
response in human PBMCs (Cardin et al., 2009), conﬁrming TLR-9 as
the primary sensor for NAPs. REP 2031 retained the same antiviral
activity as REP 2006 in preventing CMV infection (Cardin et al.,
2009) and could also block HCV infection of the liver in vivo
(Matsumura et al., 2009) and was not accompanied by hepatotox-
icity or splenomegaly, illustrating that the antiviral effects of NAPs
in vivo were not derived from pro-inﬂammatory/
immunostimulatory properties.
Oligonucleotides with polypyrimidine tracts (i.e. REP 2031) also
form obligate homotetramers (i-motif DNA) at acidic pH (Leroy
et al., 1993; Kanehara et al., 1997). This activity neutralizes the
amphipathic feature of REP 2031 at acidic pH and also renders it
stable to acid hydrolysis at pH 1 (Bernstein et al., 2008). The con-
servation of antiviral effect of REP 2031 against CMV and HCV
infection in vivo not only excluded pro-inﬂammatory/
immunostimulatory effects as part of the antiviral mechanism but
also demonstrated that the entry-inhibitory effects of NAPs for CMV
and HCV involved activity at a neutral pH. Additionally, the pH
stability of REP 2031 made possible its delivery through the
gastrointestinal tract and when combined with intestinal perme-
ation enhancers, oral administration of naked REP 2031 was shown
to have antiviral effect against CMV infection in the liver (Cardin
et al., 2009).
However, while REP 2031was able to block entry of DHBV, it had
Table 1
Optimization of NAPs for clinical use in HBV/HDV infection.
NAP Sequencea Activity Tolerability in vivo
In vivo (DHBV) Clinically
REP 2006 (dN)40 YES NA Poorf
REP 2031 (dC)40 (loss of activity at acidic pH) NOc NA Good
REP 2055 (dAdC)20b YESd YES Goodg
REP 2139 (20OMeA, 20OMe-5-MeC)20b YESe YES Goodh
d ¼ deoxyribonucleic acid, N ¼ degenerate sequence (random A, G, T or C at every position), NA ¼ not assessed.
a All linkages are phosphorothioated.
b See Fig. 1 for structure.
c Blocks viral entry of CMV and HCV in vivo.
d Also blocks viral entry of HCV in vivo.
e Unpublished data (Brikh et al., 2015).
f Due to CpG content.
g Signiﬁcant administration related side effects in humans.
h Administration well tolerated in humans (REP 2139-Ca).
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et al., 2013a), strongly suggesting that the unique post entry ef-
fect of NAPs in DHBV infection occurs intracellularly in an acidiﬁed
compartment. In vivo, treatment of ducks with REP 2031 was well
tolerated, but failed to prevent DHBV-infection in ducks (Noordeen
et al., 2013b), indicating that the post entry effect of NAPs is
essential for the prophylactic activity in DHBV infection in vivo.
An additional optimization of the REP 2031 sequence recovered
well tolerated post-entry NAP activity in DHBV infection. This
involved “doping” the polypyrimidine sequence of REP 2031 with a
purine nucleotide (adenosine) at every other position, yielding REP
2055 (Table 1), a 40mer NAP still devoid of CpG activity (Noordeen
et al., 2015) but incapable of tetramerization (and loss of amphi-
pathicity) at acidic pH (Geinguenaud et al., 2000). This NAP was
able to prevent DHBV infection in ducks and block liver infection by
HCV in Scid/Hu mice and was well tolerated in both models
(Matsumura et al., 2009; Noordeen et al., 2013b). Finally, to address
administration tolerability issues observed with REP 2055 in hu-
man subjects (Al-Mahtab et al., 2016), additional oligonucleotide
modiﬁcations were introduced to further suppress any residual
pro-inﬂammatory activity which consisted of 5-methylation of
each cytosine base and 20O-methyl modiﬁcation of each ribose
sugar (see Fig.1 and Table 1). Thesemodiﬁcations occur naturally in
mammalian DNA (Ehrlich et al., 1982; Kiss, 2001) and are known to
block TLR recognition of oligonucleotides (Kariko et al., 2005; Judge
et al., 2006; Robbins et al., 2007). This new NAP, REP 2139, was
additionally formulated as a calcium chelate complex (REP 2139-
Ca) to block chelation effects during administration common to
PS-ONs (Mata et al., 2000).
7. NAPs: therapeutic effects in vivo and current mechanistic
hypothesis in HBV
The therapeutic potential of REP 2055 to treat chronic HBV
infection was assessed by treating ducks 2 weeks after DHBV
infection, which has been previously shown to reliably result in
persistent (>280 days) DHBV infection (Foster et al., 2003). A series
of experiments evaluating different treatment doses and dosing
regimens as long as 28 days were conducted (Noordeen et al.,
2015). In these studies, all control animals treated with normal
saline maintained a chronic DHBV infection throughout the course
of the experiment whereas REP 2055 treatment was accompanied
by the reduction and or clearance of duck HBsAg (DHBsAg) in the
blood with simultaneous increases in serum titers of anti-DHBsAg
antibodies and decreases in serum DHBV DNA. At the end of
treatment, DHBsAg was found in the livers of many animals despite
clearance from the blood, suggesting that NAPs block the release ofDHBsAg from infected hepatocytes. Moreover, although reductions
in serum DHBV DNA >3 log were observed in all treated ducks,
many maintained persistent serum DHBV DNA titers (105-106
copies/ml) despite clearance of serum DHBsAg. Similar to HBV
infection in humans, DHBV infection results in the production of
non-infectious subviral particles (SVPs) that outnumber infectious
virus by more than 10,000 to 1 (Ganem and Prince, 2004; Franke
et al., 2007). The unusual observation of persistent DHBV DNA ti-
tres, despite clearance of serum DHBsAg, is consistent with a se-
lective effect of NAPs on secretion of SVPs (see Fig. 3).
Of particular interest in these in vivo studies was the absence of
viremia that persisted after REP 2055 therapy was discontinued in
these studies: 55% of treated ducks maintained suppression of
serum DHBsAg and DHBV DNA which was accompanied by the
clearance of DHBsAg, DHBV core antigen, DHBV DNA and cccDNA
from the liver during the 16 weeks of follow up after treatment,
suggesting the establishment of a durable control of infection with
relatively short duration REP 2055 treatment. The durable control
of infection observed in DHBV-infected ducks with REP 2055
cannot be achieved in the duck model with other antiviral agents
such as pencyclovir, entecavir and adefovir (Lin et al., 1998; Nicoll
et al., 1988; Le Guerhier et al., 2003; Foster et al., 2003), which
effectively clears circulating DHBV DNA but does not affect
circulating DHBsAg levels. This suggests that the unique effect of
NAPs of clearing DHBsAg from the blood may play a role in the
establishment of durable control of infection observed with REP
2055.
Based on the structure activity relationship of NAPs in DHBV and
the antiviral effects observed in the duck model, the current
mechanistic hypothesis (Fig. 3) is that in vivo, NAPs enter infected
hepatocytes and interfere with some aspect of SVP assembly or
trafﬁcking through an acidiﬁed compartment in the secretory
pathway which prevents the release of SVPs into the circulation.
This is consistent with the lack of post-entry/in vivo activity with
REP 2031 and the observation of persistent DHBV DNA (virons) in
the circulation in the absence of detectable DHBsAg as discussed
above.
SVPs share many biochemical similarities to human serum HDL
(Galvanes et al., 1982), suggesting that some aspect of apolipopro-
tein metabolism may be involved in their assembly and or secre-
tion. Moreover, apolipoprotein H, a component of HDL, is a known
ligand of HBsAg (Medhi et al., 1994, 2008). The heparin-like fea-
tures of PS-ONs (as described above) may drive apolipoprotein
interactions that interfere with SVP assembly and or transit but this
remains to be proven. The identiﬁcation of target(s) for NAP
interaction which are involved in their post-entry activity in HBV
are currently the focus of ongoing investigation.
Fig. 3. Particle production in HBV infected hepatocytes (A) and current model for the
mechanism of action of NAPs (B). In this model, the secretion of subviral particles is
selectively blocked by NAPs.
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The clinical impact of REP 2055 on treatment naïve subjects
with HBeAg positive chronic HBV infection was assessed in a small
proof of concept clinical trial (REP 101 study, Al-Mahtab et al., 2016)
using dosing regimens drawn from previous clinical studies with
antisense PS-ONs targeting liver disease (Kastelein et al., 2006). In
this trial, patients either had demonstrable maternal transmission
of their HBV infection or were HBsAg positive for at least 6 months
prior to treatment. The effects of REP 2055 monotherapy in these
patients were remarkably similar to those observed in DHBV
infected ducks in vivo: in 7/8 patients, treatment was accompanied
by reduction or clearance of serumHBsAg up to 7 logs frombaseline
(in some cases resulting in HBsAg loss) which was accompanied by
the appearance of anti-HBsAg antibodies, HBeAg seroconversion
and reduction of serum HBV DNA. Moreover, during therapy, some
patients experienced protracted periods of HBsAg loss where sub-
stantial titers of HBV DNA (~105 copies/ml) still persisted in theblood suggesting that the post-entry mechanism postulated in
DHBV infection (selective blockage of SVP particle secretion) might
also be occurring in human HBV infection. Four responder patients
also experienced transient elevations in liver transaminases. These
transaminase ﬂareswere not accompanied by any other evidence of
liver dysfunction andwere timedwith the reduction or clearance of
viremia and self-resolved with continuing REP 2055 therapy. Also
similar to the previous duck studies, 3/7 responders maintained
suppression of serum viremia (serum HBV DNA < 1000 copies/ml
and HBsAg < 1 IU/ml) for 1 year after treatment was stopped, with
two of these patients currently having no detectable serum HBV
DNA and HBsAg  LLOQ (0.05 IU/ml) 4.5e5 years off treatment.
Chronic REP 2055 treatment for more than 1 year was well
tolerated in these patients except for administration side-effects
common for PS-ONs administered by IV infusion (Tolcher et al.,
2004; Chi et al., 2005). These included shivering, fever and head-
ache which resolved after administration but which required
extended infusion times and or the use of supportive therapy
during administration. To address this tolerability issue a new NAP
compound, REP 2139, was designed and prepared as a calcium
chelate complex (REP 2139-Ca, see above).
Overexpression of the large form of HBsAg (LHBsAg) in trans-
genic mice is associated with hepatotoxicity (Chisari et al., 1987)
and with the observations in the duck model indicating that the
post-entry activity of NAPs involves blockade of HBsAg release
(Noordeen et al., 2015), there has been some debate as to the po-
tential for liver toxicity with NAPs due to the possibility of accu-
mulation of HBsAg within hepatocytes. The fate of intracellular
HBsAg with NAP treatment is currently unknown, however in
DHBV infection, NAP therapy was not accompanied by any signs of
liver dysfunction and DHBsAg was ultimately absent from the livers
of ducks which maintained control of infection off treatment
(Noordeen et al., 2015). Moreover, reduction of serum HBsAg in
human patients exposed to NAP therapy was associated with
transient elevation of serum transaminases in some but not all
patients (Al-Mahtab et al., 2016). The lack of a clear link between
surface antigen reduction in the serum and liver toxicity with NAP
therapy in vivo and in the clinic suggests that if surface antigen
accumulation is occurring with NAP therapy that it is not causing
any signiﬁcant liver dysfunction.
In a second proof of concept trial conducted in patients with
HBeAg positive chronic HBV infection, REP 2139-Ca monotherapy
had antiviral effects comparable to REP 2055 but was not accom-
panied by administration tolerability issues (REP 102 study, Al-
Mahtab et al., 2016). In this trial, 9/12 patients achieving re-
ductions in serum HBsAg and HBV DNA >2 log from baseline were
permitted to undergo short term combination therapy (13e26
weeks) with immunotherapies approved for use in HBV at the trial
site (pegylated interferon alpha 2a or thymosin alpha 1). With
either of these therapies, rapid and substantial increases
(>200 mIU/ml) in serum anti-HBsAg antibody titers were observed
within 5e10 weeks in all patients (9/9) receiving combination
therapy, a response highly unusual with immunotherapy when
used alone in patients with HBeAg þ chronic HBV infection (Lau
et al., 2005; Marcellin et al., 2016). After withdrawal of treatment,
8/9 patients initially achieved serum HBV DNA < LLOQ (116 copies/
ml) and 3 further maintained persistent suppression of serum
viremia (HBV DNA < 1000 copies/ml and HBsAg <1 IU/ml) for more
than 2 years after stopping therapy.
Initial, unpublished interim results from an ongoing proof of
concept trial at a second trial site in Caucasian patients with chronic
HBV/HDV co-infection (Bazinet et al., 2016) have conﬁrmed the
ability of REP 2139-Ca monotherapy to achieve clearance of serum
HBsAg and appearance of anti-HBsAg antibodies. Additionally, in
those patients achieving HBsAg <1 IU/ml, the same synergistic
A. Vaillant / Antiviral Research 133 (2016) 32e4038antiviral response to pegylated interferon alpha 2a was observed as
in the REP 102 study. Moreover, REP 2139-Ca treatment was also
accompanied by the clearance of serum HDV RNA. The mechanisms
underlying this additional antiviral effect against HDV are still
under investigation.9. Future perspectives
Given the established therapeutic activity of NAPs against HBV
and HDV infection in vivo and in several preliminary clinical in-
vestigations, the elucidation of the molecular basis for the clear-
ance of HBsAg and HDV RNA from the blood by NAPsmay lead to an
improved understanding of the HBV and HDV lifecycle. In-
vestigations into the post-entry antiviral mechanisms of NAPs in
HBV and HBV/HDV infections are underway in earnest. Notwith-
standing this, the current pattern of antiviral effects of NAPs in vivo
and in patients support the general hypothesis that NAPs act to
block HBsAg release from infected hepatocytes (perhaps selectively
for SVPs) by some non-immunostimulatory mechanism inside
infected cells and demonstrate that NAP therapy can achieve sub-
stantial reduction or clearance of serum HBsAg in chronic HBV
infection.
Of particular interest is the observation that the antiviral effects
of two different immunotherapies (pegylated interferon alpha 2a
and thymosin alpha 1) appear to be dramatically improved after
clearance of HBsAg from the blood in human subjects (Al-Mahtab
et al., 2016). The HBsAg protein is the most abundant circulating
viral antigen and has been linked to immunosuppression in HBV
infection (Kondo et al., 2013). Its clearance from the blood during
therapy is recognized as the most reliable indicator of persistence
of suppression of viremia off treatment (Frenette and Gish, 2009;
Moucari et al., 2009). Moreover, the HBsAg protein has been
shown to directly block both adaptive and innate immune pro-
cesses (Vanlandschoot et al., 2002; Cheng et al., 2005; Op den
Brouw et al., 2008; Wu et al., 2009; Xu et al., 2009; Shi et al.,
2012) suggesting that circulating HBsAg may not only play a role
in suppression of the host immune response to HBV infection but
may also interfere with its simulation by immunotherapy.
The initial in vivo and clinical investigations described above
provide important preliminary observations of the antiviral effects
of NAPs in chronic HBV infection. However additional controlled
trials will be required to clearly deﬁne the full clinical impact of NAP
therapy in the treatment of HBV infection and HBV/HDV co-
infection. The ﬁrst of these planned trials is underway and will
assess the safety and antiviral activity of add-on treatment of REP
2139-Ca and pegylated interferon alpha 2a in patients with HBeAg
negative chronic HBV infection already on treatment with tenofovir
disoproxil fumarate (REP 401 study, NCT02565719). Additional
combination therapy trials with NAPs would also be useful to
examine the effects of HBsAg clearance on the efﬁcacy of thera-
peutic vaccines and other therapeutic approaches currently in
development as reviewed by Block et al., 2015.Acknowledgements
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